News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
Settle® was one of the treatments assessed in a research abstract presented at the 2025 Bain Fallon Memorial Lectures in Australia and published in SciQuest. Settle improved pregnancy outcomes in BHS-positive mares.
An abstract presented at the 2024 International Embryo Technology Society meeting summarizes a research study showing that a single treatment of Amplimune 7 days after parturition may help prevent metritis in dairy cows.
Settle® immunotherapy for equine endometritis is now available in Canada. It's also sold in the USA, Australia, New Zealand and UAE. Settle is compatible with conventional treatments and is safe with natural breeding or AI.
NovaVive's immunotherapy for equine endometritis, Settle®, has received approval for sale in Canada from the Canadian Food Inspection Agency (CFIA). The product is expected to launch in the first quarter of this year.
An abstract has been presented at the 2023 AETA & CETA/ACTE Joint Convention in Orlando, FL summarizing a study showing a positive effect of MCWF (Amplimune) on pregnancy per embryo transfer for dairy cows with one lactation.
Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.